#1337

Prostate Artery Embolisation safety and efficacy: an Australian multi-centre review

J. Bruinsma¹, Z. Melvin², W. Ormiston²

¹Sir Charles Gairdner Hospital, Urology, Perth, Australia
²Sir Charles Gairdner Hospital, Radiology, Perth, Australia

Introduction:

Benign prostatic hyperplasia (BPH) commonly causes moderate-to-severe lower urinary tract symptoms (LUTS) and may result in indwelling catheter (IDC) dependence. Prostate artery embolisation (PAE) is gaining traction as a minimally invasive alternative to medical and surgical therapies. This study evaluates the effectiveness of PAE in improving symptom scores, quality of life (QoL), and catheter independence in a Western Australian population.

Material and methods:

We retrospectively reviewed 74 PAE procedures performed across two Perth hospitals between September 2019 and February 2025. Patients included those with significant LUTS (n=46) or IDC dependence (n=28). Pre- and post-procedure data—including IPSS, QoL, prostate volume, and catheter status—were gathered via institutional records, imaging, and structured phone interviews. Mean follow-up was 108 days.

Results:

A total of 74 procedures were performed with a mean patient age of 75. Mean prostate volume in the LUTS group was 150cc and 180cc in the IDC group. PAE led to a significant reduction in IPSS (20.1 to 5.7, p < 0.00001) and QoL scores (4.6 to 1.2, p < 0.00001). 61% of IDC dependent patients had successful removal of catheter post-operatively. Volume of embolic used was moderately correlated with improvement in QoL scores (r = +0.41, p = 0.046) in the LUTS sub-group. There were 3 complications (4%).